Compare ICCM & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | AIDX |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | 2013 | 2025 |
| Metric | ICCM | AIDX |
|---|---|---|
| Price | $0.72 | $0.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | 110.0K | ★ 235.3K |
| Earning Date | 11-18-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,045,133.00 |
| Revenue This Year | $27.11 | $44.20 |
| Revenue Next Year | $104.97 | $95.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.13 | $0.18 |
| 52 Week High | $9.54 | $18.96 |
| Indicator | ICCM | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 29.69 | 33.68 |
| Support Level | $0.65 | $0.18 |
| Resistance Level | $0.74 | $0.27 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 18.43 | 23.17 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.